Системная красная волчанка sle-dac
Латекс-тесты. “Филисит-Диагностика”, Украина
Латекс-тесты, ДАС, Молдова
ДИАГНОСТИЧЕСКИЕ НАБОРЫ ДЛЯ КЛИНИЧЕСКОЙ ИММУНОЛОГИИ, производство ДАС, Молдова
Полный текст:
115522, Москва, Каширское шоссе, 34А;
119991, Москва, ул. Трубецкая, 8, стр. 2
1. Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing lowdose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61-4. doi: 10.1136/ard.2008.102533
2. Bexelius C, Wachtmeister K, Skare P,et al. Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports. Lupus. 2013;22:793-801. doi: 10.1177/0961203313491849
3. Eder L, Urowitz MB, Gladman DD. Damage in lupus patients – what have we learned so far? Lupus. 2013 Oct;22(12):1225-31.
4. Rahman P, Gladman DD, Urowitz MB, et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10(2):93-6. doi: 10.1191/096120301670679959
5. Wilhelm TR, Magder LS, Petri M. Remission in systemic lupus erythematosus: durable remission is rare. Ann Rheum Dis. 2017 Mar;76(3):547-53. doi: 10.1136/annrheumdis-2016-209489
6. Dubois EL. Lupus Erythematosus. 2 nd ed. Los Angeles: University of Southern California Press; 1976. 243 p.
7. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73:958-67. doi: 10.1136/annrheumdis-2013-205139
8. Steiman AJ, Urowitz MB, Ibanez D, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol. 2014;41:1808-16. doi: 10.3899/jrheum.131137
9. Van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017 Mar;76(3):554-61. doi: 10.1136/annrheumdis-2016-209519. Epub 2016 Nov 24.
10. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016 Sep;75(9):1615-21. doi: 10.1136/annrheumdis-2015-207726
11. Heller CA, Schur PH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol. 1985 Oct;12(5):916-8.
12. Drenkard C, Villa AR, Garcia-Padilla C, et al. Remission of systematic lupus erythematosus. Medicine (Baltimore). 1996;75:88-98. doi: 10.1097/00005792-199603000-00005
13. Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol. 2005 Aug;32(8):1467-72.
14. Medina-Quinones CV, Ramos-Merino L, Ruiz-Sada P, Isenberg D. Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res (Hoboken). 2016 Jul;68(7):981-7. doi: 10.1002/acr.22774
15. Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis. 2015;74:2117-22. doi: 10.1136/annrheumdis-2015-207347
16. Tselios K, Gladman DD, Touma Z, et al. Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23720
17. Aljohani R, Gladman DD, Su J, Urowitz MB. Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. Clin Rheumatol. 2017 Aug;36(8):1773-8. doi: 10.1007/s10067-017-3713-7
18. Mok CC, Wong RW, Lau CS. Lupus nephritis in Southern Chinese patients: clinic-pathologic findings and long-term outcome. Am J Kidney Dis. 1999;34:315-23. doi: 10.1016/S0272-6386(99)70361-6
19. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46:995-1002. doi: 10.1002/art.10142
20. Lee BS, Cho HY, Kim EJ, et al. Clinical outcomes of childhood lupus nephritis: a single center’s experience. Pediatr Nephrol. 2007;22:222-31. doi: 10.1007/s00467-006-0286-0
21. So MW, Koo BS, Kim YG, et al. Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis. Clin Rheumatol. 2011;30:1399-405.
22. Fernandes das Neves M, Irlapati RV, Isenberg D. Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years. Rheumatology (Oxford). 2015;54:1403-7. doi: 10.1093/rheumatology/kev003
23. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016 Oct;12(10):605-20.
24. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012 Jul;51(7):1145-53. doi: 10.1093/rheumatology/ker410
25. Iaccarino L, Andreoli L, Bartoloni Bocci L, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018;86:1-8. doi: 10.1016/j.jaut.2017.09.004
26. Kraaij T, Kamerling WA, de Rooij NM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45-54. doi: 10.1016/j.jaut.2018.03.003
27. Bruce IN, Urowitz M, van Vollenhoven R, et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 2016 Jun;25(7):699-709.
28. Doria A, Bass D, Schwarting A, et al. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Lupus. 2018 Aug;27(9):1489-98. doi: 10.1177/0961203318777634
29. Beckwith H, Lightstone L. Rituximab in systemic lupus erythematosus and lupus nephritis. Nephron Clin Pract.2014;128(3-4):250-4. doi: 10.1159/000368585
30. Alshaiki F, Obaid E, Almuallim A, et al. Outcomes of rituximab therapy in refractory lupus: A meta-analysis. Eur J Rheumatol. 2018 Jul;5(2):118-26. doi: 10.5152/eurjrheum.2018.17096
31. Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: longterm steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2017;4:e000182. doi: 10.1136/lupus-2016-000182
32. Меснянкина АА, Соловьев СК, Асеева ЕА, Насонов ЕЛ. Эффективность генно-инженерной биологической терапии и особенности гуморального иммунитета у больных системной красной волчанкой. Научно-практическая ревматология. 2018;56(3):302-9. doi: 10.14412/1995-4484-2018-302-309
Контент доступен под лицензией Creative Commons Attribution 4.0 License.
Полный текст:
Виктория Александровна Лила
191015, Санкт-Петербург, ул. Кирочная, 41
1. Соловьев СК. Системная красная волчанка. В кн.: Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. С. 113-36.
2. Клюквина НГ, Насонов ЕЛ. Особенности клинических и лабораторных проявлений системной красной волчанки. Современная ревматология. 2012;6(4):40-8.
3. Лила АМ, Трофимов ЕА, Лила ВА. Системная красная волчанка: особенности течения у беременных и варианты терапии. Современная ревматология. 2015;9(3):43-7.
4. Мазуров ВИ, редактор. Диффузные болезни соединительной ткани: руководство для врачей. Санкт-Петербург: СпецЛит; 2009. 192 с. [ Mazurov VI, editor. Diffuznye bolezni soedinitel'noi tkani: rukovodstvo dlya vrachei
5. Лапин СВ, Тотолян АА. Иммунологическая лабораторная диагностика аутоиммунных заболеваний. Санкт-Петербург: Человек; 2010. 272 с.
6. Созина АВ. Клинико-иммунологические взаимосвязи при системной красной волчанке и других болезнях соединительной ткани. Автореф. дисc. канд. мед. наук. Санкт-Петербург; 2007. 22 с.
7. Beutner EH, Holborow EJ, Johnson GD. A new fluorescent antibody method: Mixed antiglobulin immunofluorescence or labelled antigen indirect immunofluorescence staining. Nature. 1965 Oct 23;208(5008):353-5.
10. Crowson AN, Magro CM. Cutaneous histopathology of lupus erythematosus. Diagn Histopathol. 2009;15:157–85.
11. Meurer M. Immunopathology of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editros. Cutaneous Lupus Erythematosus. Springer-Verlag: Berlin; 2005. P.305-10.
12. Gilliam JN. The significance of cutaneous immunoglobulin deposits in lupus erythematosus and NZB/NZW F1 hybrid mice. J Invest Dermatol. 1975 Jul;65(1):154-61.
13. Meurer M, Gigli J. Interaction of DNA with the early components of complement. J Invest Dermatol. 1978;70:223.
14. Gangaram HB, Kong NC, Phang KS, Suraiya H. Lupus band test in systemic lupus erythematosus. Med J Malaysia. 2004 Dec;59(5):638-48.
15. Casciola-Rosen L, Rosen L. Ultraviolet light-induced apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus. 1997;6(2):175-80.
16. Reich A, Meurer M, Viehweg A, Muller DJ. Narrow-band UVB induced externalization of selected nuclear antigens in keratinocytes: implications for lupus erythematosus pathogenesis. Photochem Photobiol. 2009 Jan-Feb;85(1):1-7. doi: 10.1111/j.17511097.2008.00480.x. Epub 2008 Dec 8.
17. Ahmed AR, Provost TT. The incidence of a positive lupus band test using sun-exposed and unexposed skin. Arch Dermatol. 1979 Feb;115(2):228-9.
18. Dahl MV. Usefulness of direct immunofluorescence in patients with lupus erythematosus. Arch Dermatol. 1983 Dec;119(12):1010-7.
19. Reich A, Marcinow K, Bialynicki-Birula R. The lupus band test in systemic lupus erythematosus patients. Ther Clin Risk Manag. 2011 Jan 24;7:27-32. doi: 10.2147/TCRM.S10145.
20. Sontheimer RD, Provost TT. Cutaneous manifestations of lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois’ lupus erythematosus. 5th ed. Baltimore: Williams & Wilkins; 1997. P. 569–623.
21. Cardinali C, Caproni M, Fabbri P. The composition of the lupus band test (LBT) on the sun protected non lesional (SPNL) skin in patients with cutaneous lupus erythematosus (CLE). Lupus. 1999;8(9):755-60.
22. Wojnarowska F, Bhogal B, Black MM. The significance of an IgM band at the dermo-epidermal junction. J Cutan Pathol. 1986 Oct;13(5):359-62.
23. Mehta V, Sarda A, Balachandran C. Lupus band test. Indian J Dermatol Venereol Leprol. 2010 May-Jun;76(3):298-300. doi: 10.4103/0378-6323.62983.
24. Mysorekar VV, Sumathy TK, Shyam Prasad AL. Role of direct immunofluorescence in dermatological disorders. Indian Dermatol Online J. 2015 May-Jun;6(3):17280. doi: 10.4103/2229-5178.156386.
25. Provost TT, Andres G, Maddison PJ, Reichlin M. Lupus band test in untreated SLE patients: correlation of immunoglobulin deposition in the skin of the extensor forearm with clinical renal disease and serological abnormalities. J Invest Dermatol. 1980 Jun;74(6):407-12.
27. Sontheimer RD, Gilliam JN. A reappraisal of the relationship between subepidermal immunoglobulin deposits and DNA antibodies in systemic lupus erythematosus: a study using the crithidia lucillae immunofluorescence anti-DNA assay. J Invest Dermatol. 1979 Jan;72(1):29-32.
28. Carvalho MF, Coelho RA. Lupus band test: diagnostic value in disseminated lupus erythematosus. Acta Med Port. 1991 SepOct;4(5):242-8.
30. Leibold AM, Bennion S, David-Bajar K, Schleve MJ. Occurrence of positive immunofluorescence in the dermoepidermal junction of sun-exposed skin of normal adults. J Cutan Pathol. 1994 Jun;21(3):200-6.
31. Fabre VC, Lear S, Reichlin M, et al. Twenty percent of biopsy specimens from sun-exposed skin of normal young adults demonstrate positive immunofluorescence. Arch Dermatol. 1991 Jul;127(7):1006-11.
32. Liu T, Liu FR. Prognostic value of lupus band test in unexposed normal skin of patients with systemic lupus erythematosus. Chin Med J (Engl). 1989 Aug;102(8):620-4.
33. Halberg P, Ullman S, Jorgensen F. The lupus band test as a measure of disease activity in systemic lupus erythematosus. Arch Dermatol. 1982 Aug;118(8):572-6.
34. Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol. 2001 Jan;28(1):1-23.
35. Magro CM, Crowson AN. The immunofluorescent profile of dermatomyositis. A comparative study with lupus erythematosus. J Cutan Pathol. 1997 Oct;24(9):543-52.
36. Shibeshi D, Blaszczyk M, JarzabekChorzelska M, et al. Immunopathologic findings in systemic sclerosis patients: clinical and immunopathologic relationships. Int J Dermatol. 1989 Dec;28(10):650-6.
37. Davis BM, Gilliam AN. Prognostic significance of subepidermal immune deposits in uninvolved skin of patients with systemic lupus erythematosus: 10 year longitudinal study. J Invest Dermatol. 1984 Oct;83(4):242-7.
38. Zecevic RD, Pavlovic MD, Stefanovic D. Lupus band test and disease activity in systemic lupus erythematosus: does it still matter. Clin Exp Dermatol. 2006 May;31(3):358-60.
Контент доступен под лицензией Creative Commons Attribution 4.0 License.
Читайте также:
- Половые инфекции и спайки
- Как лечить инфекции крайней плоти
- Кишечной инфекции при целиакии
- Иммуномодуляторы при стрептококковой инфекции
- Трансфер фактор от папиломо-вирусной инфекции
Copyright © Иммунитет и инфекции